Denali Therapeutics Inc.
US ˙ NasdaqGS ˙ US24823R1059

SecurityDNLI / Denali Therapeutics Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership2,692,175 shares
Latest Disclosed Value $ 51,686,812
Dimensional Fund Advisors Lp reports 13.39% increase in ownership of DNLI / Denali Therapeutics Inc.

On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 2,692,175 shares of Denali Therapeutics Inc. (US:DNLI) valued at $51,689,760 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 2,374,303 shares of Denali Therapeutics Inc.. This represents a change in shares of 13.39% during the quarter. The current value of the position is $52,551,256 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F DENALI THERAPEUTICS COM 24823R105 2,692,175 317,872 13.39 51,687 31.86 0.0107
2026-02-12 2025-12-31 13F DENALI THERAPEUTICS COM 24823R105 2,374,303 17,089 0.72 39,198 14.53 0.0082
2025-11-12 2025-09-30 13F DENALI THERAPEUTICS COM 24823R105 2,357,214 -55,714 -2.31 34,226 1.39 0.0073
2025-08-12 2025-06-30 13F DENALI THERAPEUTICS COM 24823R105 2,412,928 312,072 14.85 33,759 18.16 0.0078
2025-05-13 2025-03-31 13F DENALI THERAPEUTICS COM 24823R105 2,100,856 245,820 13.25 28,570 -24.43 0.0071
2025-02-13 2024-12-31 13F DENALI THERAPEUTICS COM 24823R105 1,855,036 295,594 18.96 37,805 -16.78 0.0091
2024-11-07 2024-09-30 13F DENALI THERAPEUTICS COM 24823R105 1,559,442 141,970 10.02 45,429 38.03 0.0110
2024-08-09 2024-06-30 13F DENALI THERAPEUTICS COM 24823R105 1,417,472 84,522 6.34 32,913 20.33 0.0086
2024-05-10 2024-03-31 13F DENALI THERAPEUTICS COM 24823R105 1,332,950 213,322 19.05 27,352 13.83 0.0074
2024-02-07 2023-12-31 13F DENALI THERAPEUTICS COM 24823R105 1,119,628 146,394 15.04 24,030 19.67 0.0070
2023-11-09 2023-09-30 13F DENALI THERAPEUTICS COM 24823R105 973,234 218,433 28.94 20,080 -9.85 0.0066
2023-08-09 2023-06-30 13F DENALI THERAPEUTICS COM 24823R105 754,801 127,476 20.32 22,274 54.16 0.0071
2023-05-12 2023-03-31 13F DENALI THERAPEUTICS COM 24823R105 627,325 69,067 12.37 14,450 96,226.67 0.0049
2023-02-09 2022-12-31 13F DENALI THERAPEUTICS COM 24823R105 558,258 -51,581 -8.46 16 -99.92 0.0046
2022-11-10 2022-09-30 13F DENALI THERAPEUTICS COM 24823R105 609,839 -281,839 -31.61 18,711 -28.69 0.0072
2022-08-12 2022-06-30 13F DENALI THERAPEUTICS COM 24823R105 891,678 13,454 1.53 26,239 -7.13 0.0094
2022-05-13 2022-03-31 13F DENALI THERAPEUTICS COM 24823R105 878,224 106,027 13.73 28,253 -17.97 0.0087
2022-02-09 2021-12-31 13F DENALI THERAPEUTICS COM 24823R105 772,197 137,462 21.66 34,441 7.56 0.0104
2021-11-12 2021-09-30 13F DENALI THERAPEUTICS COM 24823R105 634,735 309,387 95.09 32,021 25.49 0.0103
2021-08-12 2021-06-30 13F DENALI THERAPEUTICS COM 24823R105 325,348 -95,854 -22.76 25,517 6.16 0.0081
2021-05-14 2021-03-31 13F DENALI THERAPEUTICS COM 24823R105 421,202 -31,578 -6.97 24,036 -36.63 0.0080
2021-03-08 2020-12-31 13F/A-2 DENALI THERAPEUTICS COM 24823R105 452,780 -82,339 -15.39 37,931 97.81 0.0137
2021-02-11 2020-12-31 13F DENALI THERAPEUTICS COM 24823R105 452,780 -82,339 37,931 13,698.6611
2020-11-12 2020-09-30 13F DENALI THERAPEUTICS COM 24823R105 535,119 -15,578 -2.83 19,175 44.02 0.0081
2020-08-13 2020-06-30 13F DENALI THERAPEUTICS COM 24823R105 550,697 -13,162 -2.33 13,314 34.74 0.0059
2020-05-14 2020-03-31 13F DENALI THERAPEUTICS COM 24823R105 563,859 42,193 8.09 9,881 8.74 0.0051
2020-02-14 2019-12-31 13F DENALI THERAPEUTICS COM 24823R105 521,666 123,343 30.97 9,087 48.87 0.0033
2019-11-12 2019-09-30 13F DENALI THERAPEUTICS COM 24823R105 398,323 193,781 94.74 6,104 43.76 0.0024
2019-08-13 2019-06-30 13F DENALI THERAPEUTICS COM 24823R105 204,542 204,542 4,246 0.0016
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.